Quick Dispatch:
Your tirzepatide surpass SURPASS-2: A Study of Tirzepatide Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes – My Endo Consult orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your tirzepatide surpass SURPASS-2: A Study of Tirzepatide Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes – My Endo Consult ships.
Need Help?
Questions about tirzepatide surpass SURPASS-2: A Study of Tirzepatide Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes – My Endo Consult, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for tirzepatide surpass SURPASS-2: A Study of Tirzepatide Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes – My Endo Consult in your area.
![Efficacy of tirzepatide in phase 2 (GPGB; [14]) and phase 3 (SURPASS-1](https://www.researchgate.net/publication/363201315/figure/fig3/AS:11431281082605778@1662084799021/Efficacy-of-tirzepatide-in-phase-2-GPGB-14-and-phase-3-SURPASS-1-to-5-15-19.png)
Efficacy of tirzepatide in phase 2 (GPGB; [14]) and phase 3 (SURPASS-1
22.54
Tirzepatide is finally here – what's the big deal? – GP Voice
25.78
Tirzepatide Protocol Training as Medical Weight Loss Treatment
29.20
In the SURPASS-CVOT head-to-head trial involving over 13,000 adults with T2D and ASCVD, tirzepatide (Mounjaro) matched dulaglutide in reducing major cardiovascular events (8% lower risk) and significantly cut all-cause mortality by 16%
22.81
Frias_Tirzepatide: Overview of SURPASS Trials in Patients With Type 2 Diabetes
27.06
SURPASS-CVOT Shows Mounjaro Surpasses Trulicity in CV Outcomes
24.02
SURPASS-5: Tirzepatide lowers HbA1c in adults with type 2 diabetes on insulin glargine
25.79
